Clinical Trials

Temporarily not available

Carcinoma, Non-Small-Cell Lung

NCT04830202 2026-05-13

Expanded Access to Telisotuzumab Vedotin

Carcinoma, Non-Small-Cell Lung

NCT07535359 2026-05-06

Medical Access Program for Ifinatamab Deruxtecan in 3L+ Pretreated Extensive-stage Small Cell Lung Cancer

Small Cell Lung Carcinoma

NCT05100134 2026-04-01

Managed Access Programs for LDK378, Ceritinib

LymphoidPlasma cellThoracic

Carcinoma, Non-Small-Cell Lung, Granuloma, Plasma Cell, Lymphoma, Large-Cell, Anaplastic

NCT04741789 2026-03-16

Managed Access Programs for INC280, Capmatinib

Adenocarcinoma of Lung, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT06797362 2026-02-17

Expanded Access Program of Zidesamtinib (NVL-520) for Patients With Advanced ROS1+ NSCLC or Other ROS1+ Solid Tumors

Carcinoma, Non-Small-Cell Lung

NCT07310277 2026-01-29

Expanded Access to ABBV-706

Small Cell Lung Carcinoma

NCT04566393 2026-01-28

Expanded Access to Ulixertinib (BVD-523) in Patients With Advanced MAPK Pathway-Altered Malignancies

CNSDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Esophageal Neoplasms, Glioblastoma, Head and Neck Neoplasms, Carcinoma, Hepatocellular, Melanoma, Ovarian Neoplasms, Pancreatic Neoplasms, Stomach Neoplasms, Thyroid Neoplasms, Colorectal Neoplasms, Cholangiocarcinoma

NCT03756311 2026-01-23

Expanded Access to NanoPac

GenitourinaryThoracic

Lung Neoplasms, Prostatic Neoplasms

NCT06841874 2025-12-24

Tale EAP

Carcinoma, Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, Lung Diseases, Lung Neoplasms, Neoplasms, Neoplasms by Site, Respiratory Tract Diseases, Respiratory Tract Neoplasms, Thoracic Neoplasms

NCT06132191 2025-11-20

Expanded Access Use of Cemiplimab in Patients With Solid Tumors

DermatologicThoracic

Carcinoma, Basal Cell, Carcinoma, Non-Small-Cell Lung

NCT04667234 2025-08-13

Expanded Access of Sotorasib

Carcinoma, Non-Small-Cell Lung

NCT06872489 2025-07-23

Expanded Access Protocol for the Use of SL-28 in the Treatment of Advanced Solid Tumors

CNSGastrointestinalHead & NeckThoracic

Carcinoma, Non-Small-Cell Lung, Gastrointestinal Neoplasms, Head and Neck Neoplasms, Neuroblastoma, Pancreatic Neoplasms, Recurrence

NCT06279728 2025-07-03

Medical Access Program for Datopotamab Deruxtecan in EGFRm NSCLC Patients

EGFRm Advanced Non-Small Cell Lung Cancer

NCT04599712 2025-06-13

Pre-Approval Access With Amivantamab (JNJ-61186372) in Participants With Metastatic Non-Small Cell Lung Cancer

Carcinoma, Non-Small-Cell Lung

NCT06099639 2025-06-08

Medical Access Program for Patritumab Deruxtecan

Epidermal Growth Factor Receptor (EGFR)-Mutated Non Small Cell Lung Cancer

NCT04100694 2025-05-20

Early Access Program Providing HER2/HER3 Bispecific Antibody, MCLA-128, for a Patient With Advanced NRG1-Fusion Positive Solid Tumor

BreastGastrointestinalGenitourinaryHead & NeckThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Head and Neck Neoplasms, Neoplasms, Unknown Primary, Pancreatic Neoplasms, Prostatic Neoplasms, Colorectal Neoplasms, Cholangiocarcinoma

NCT06064500 2025-03-10

Tarlatamab (AMG 757) Expanded Access Protocol for Advanced Small Cell Lung Cancer

Bites and Stings, Lung Neoplasms, Small Cell Lung Carcinoma

NCT03906331 2025-01-17

Expanded Access for the Treatment of Cancers With Rearranged During Transfection (RET) Activation

BreastEndocrineGastrointestinalHead & NeckThoracic

Thyroid Cancer, Papillary, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Colonic Neoplasms, Pancreatic Neoplasms, Carcinoma, Medullary

NCT04507919 2024-11-12

Managed Access Program Cohort Treatment Plan CTMT212X2002I to Provide Access to Trametinib and Dabrafenib Combination Therapy for Patients With BRAF V600 Mutation-positive Advanced Non-Small Cell Lung Cancer

Adenocarcinoma of Lung, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Small Cell Lung Carcinoma

NCT03874455 2024-03-22

Tazemetostat Expanded Access Program for Adults With Solid Tumors

GenitourinaryOther solid neoplasmSarcomaThoracic

Mesothelioma, Malignant, Carcinoma, Renal Cell, Chondrosarcoma, Sarcoma, Sarcoma, Synovial, Rhabdoid Tumor, Desmoplastic Small Round Cell Tumor

NCT05225259 2024-02-28

Expanded Access for LOXO-260 in Participants With Cancer Caused by an Abnormal RET Gene That Did Not Respond/is no Longer Responding to Treatment With a Type of Drug Called a RET Inhibitor

Head & NeckThoracic

Carcinoma, Non-Small-Cell Lung, Thyroid Neoplasms

NCT04146571 2022-10-20

Expanded Access to Ensartinib for Participants With ALK+ NSCLC

Carcinoma, Carcinoma, Non-Small-Cell Lung

NCT04535557 2022-09-30

An Expanded Access Protocol for Mobocertinib in Refractory Non-small Cell Lung Cancer (NSCLC) Participants With Epidermal Growth Factor Receptor (EGFR) Exon20 Insertion Mutations

Carcinoma, Non-Small-Cell Lung

NCT04829422 2022-03-03

Early Access Program of Lazertinib in Republic of Korea

Lung Neoplasms

NCT04204928 2021-08-13

Pre-Approval Access Program (PAAP) for Pralsetinib (BLU-667) in Patients With Unresectable or Metastatic NSCLC or MTC

Carcinoma, Non-Small-Cell Lung, Carcinoma, Medullary

NCT04504513 2021-03-19

Expanded Access to Trilaciclib for Patients Receiving Chemotherapy for Small Cell Lung Cancer

Lung Neoplasms, Small Cell Lung Carcinoma

NCT02475382 2020-11-27

CheckMate 169

Squamous Non-Small Cell Lung Cancer

NCT01947608 2020-11-03

Expanded Treatment Protocol With LDK378 in ALK(+) NSCLC

Carcinoma, Non-Small-Cell Lung

NCT04291937 2020-06-19

A Multicenter Expanded Access Treatment Protocol of Lurbinectedin in Previously Treated SCLC in the USA

Small Cell Lung Carcinoma

NCT03554434 2020-03-02

An Expanded Access Program for AM0010 (Pegilodecakin)

BreastDermatologicGastrointestinalGenitourinaryGynecologicThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Melanoma, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Colorectal Neoplasms

NCT03178071 2019-11-04

Expanded Access For Lorlatinib For Patients With Non Small Cell Lung Cancer ALK Positive or ROS1 Positive

Non Small Cell Lung Cancer ALK Positive or ROS1 Positive

NCT03503890 2019-09-10

Expanded Access to Rovalpituzumab Tesirine

Small Cell Lung Carcinoma

NCT00684385 2019-03-14

An Expanded Access Programme With Iressa for Patients With Non-Small-Cell Lung Cancer and Cancer of the Head and Neck

Head & NeckThoracic

Carcinoma, Non-Small-Cell Lung, Head and Neck Neoplasms

NCT01931306 2018-11-14

Expanded Access Study of Afatinib in Treatment-naive or Chemotherapy Pre-treated Patients With Non-small Cell Lung Cancer (NSCLC)

Carcinoma, Non-Small-Cell Lung

NCT02547675 2018-09-25

Rociletinib (CO-1686) USA Expanded Access Program

Carcinoma, Non-Small-Cell Lung

NCT00683306 2018-09-13

Open Label Extension Study With Gefitinib (IRESSA™) for Completing Trial Patients Who May Benefit From Further Treatment

Carcinoma, Non-Small-Cell Lung

NCT02784158 2018-02-06

An Expanded Access Study of Brigatinib for Patients With ALK-positive Advanced Non-Small Cell Lung Cancer

Adenocarcinoma, Carcinoma, Carcinoma, Non-Small-Cell Lung, Carcinoma, Squamous Cell, Lung Neoplasms, Carcinoma, Large Cell

NCT02824094 2017-07-21

Crizotinib Expanded Access Protocol For ROS1 Positive NSCLC

Carcinoma, Non-Small-Cell Lung, Neoplasms

NCT02271139 2017-03-09

Expanded Access Study of Alectinib for Participants With Anaplastic Lymphoma Kinase (ALK)-Rearranged Non-Small Cell Lung Cancer (NSCLC) After Disease Progression on or Intolerance to Prior ALK Tyrosine Kinase Inhibitor Therapy

Carcinoma, Non-Small-Cell Lung

NCT01649284 2016-11-30

Afatinib Expanded Access Program

Carcinoma, Non-Small-Cell Lung

NCT01209650 2016-11-10

LUX Lung Special Access Scheme Australia Named Patient Use (NPU)

Carcinoma, Non-Small-Cell Lung

NCT02451852 2016-07-14

AZD9291 US Expanded Access Program

EGFR T790M Mutation Positive NSCLC

NCT01279798 2011-03-01

Expanded Access Multicenter Study of Lucanix® (Belagenpumatucel-L)

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT00040625 2007-03-15

ALIMTA (Pemetrexed) Alone or in Combination With Cisplatin for Patients With Malignant Mesothelioma.